TY - JOUR
T1 - Estimating the hidden burden of obstructive sleep apnoea: challenges and pitfalls
AU - Garbarino, Sergio
AU - Magnavita, Nicola
AU - Sanna, Antonio
AU - Bragazzi, Nicola Luigi
PY - 2020
Y1 - 2020
N2 - Adam Benjafield and colleagues should be congratulated for theirefforts to estimate the global burden of obstructive sleep apnoea. They did a systematic review of population studies in which obstructive sleep apnoea had been objectively assessed,
and extrapolated data to the entire country population as well as to the populations of other countries matched by age, sex, body-mass index, ethnicity, and geographical proximity. However, not all the studies included had done stratified random sampling rather than convenience sampling, and some reported a large dropout of participants. Caution is needed when dealing with data from non-randomly selected populations.
Furthermore, the matching done, even if based on established determinants of obstructive sleep apnoea, fails to recognise anthropological (such as cultural and religious) differences existing even among neighbouring countries, which could affect healthseeking behaviors, one of the main sources of underestimation.
Underestimation includes, indeed, underascertainment, in which patients with obstructive sleep apnoea might
not be aware of their status, or, if aware, do not seek physician’s advice due to stigma, cultural or religious
factors, or legal or administrative barriers. Another component of underestimation is underdiagnosis, in which a misclassification occurs due to measurement errors, the physician’s lack of experience or knowledge about testing or interpretation of results, and, especially in developing countries, lack of health-care facilities and instrumentation.
Finally, underestimated cases include also undernotified cases. Both overestimation and underestimation affect the management efficiency of health-care systems and compromises the possibility of making informed, evidence-based decisions. Indeed, it is crucial to have an accurate estimate of the number of cases undiagnosed or untreated. Benjafield and colleagues applied a conversion algorithm to reduce the problem
of underdiagnosis. However, issues
pertaining to underascertainment
and undernotification remain
unaddressed.
Apart from these methodological
considerations, the most important
message of the study1
is that the global
burden of obstructive sleap apnoea
is similar, if not even higher, to the
burden generated by other chronic
diseases such as hypertension or
diabetes. For these disorders, but not
for obstructive sleep apnoea, targeted
prevention and early diagnosis
programmes are currently being
implemented in several countries.
Lessons that we can learn and
capitalise on include the need
to improve the awareness that
obstructive sleep apnoea can be
diagnosed and treated; the need
for high-quality epidemiological
investigations, including nationwide
surveys; and the need to establish
a global registry of obstructive
sleep apnoea, given its clinical and
socioeconomic burden.
AB - Adam Benjafield and colleagues should be congratulated for theirefforts to estimate the global burden of obstructive sleep apnoea. They did a systematic review of population studies in which obstructive sleep apnoea had been objectively assessed,
and extrapolated data to the entire country population as well as to the populations of other countries matched by age, sex, body-mass index, ethnicity, and geographical proximity. However, not all the studies included had done stratified random sampling rather than convenience sampling, and some reported a large dropout of participants. Caution is needed when dealing with data from non-randomly selected populations.
Furthermore, the matching done, even if based on established determinants of obstructive sleep apnoea, fails to recognise anthropological (such as cultural and religious) differences existing even among neighbouring countries, which could affect healthseeking behaviors, one of the main sources of underestimation.
Underestimation includes, indeed, underascertainment, in which patients with obstructive sleep apnoea might
not be aware of their status, or, if aware, do not seek physician’s advice due to stigma, cultural or religious
factors, or legal or administrative barriers. Another component of underestimation is underdiagnosis, in which a misclassification occurs due to measurement errors, the physician’s lack of experience or knowledge about testing or interpretation of results, and, especially in developing countries, lack of health-care facilities and instrumentation.
Finally, underestimated cases include also undernotified cases. Both overestimation and underestimation affect the management efficiency of health-care systems and compromises the possibility of making informed, evidence-based decisions. Indeed, it is crucial to have an accurate estimate of the number of cases undiagnosed or untreated. Benjafield and colleagues applied a conversion algorithm to reduce the problem
of underdiagnosis. However, issues
pertaining to underascertainment
and undernotification remain
unaddressed.
Apart from these methodological
considerations, the most important
message of the study1
is that the global
burden of obstructive sleap apnoea
is similar, if not even higher, to the
burden generated by other chronic
diseases such as hypertension or
diabetes. For these disorders, but not
for obstructive sleep apnoea, targeted
prevention and early diagnosis
programmes are currently being
implemented in several countries.
Lessons that we can learn and
capitalise on include the need
to improve the awareness that
obstructive sleep apnoea can be
diagnosed and treated; the need
for high-quality epidemiological
investigations, including nationwide
surveys; and the need to establish
a global registry of obstructive
sleep apnoea, given its clinical and
socioeconomic burden.
KW - obstructive sleep apnea, epidemiology, pitfalls
KW - obstructive sleep apnea, epidemiology, pitfalls
UR - http://hdl.handle.net/10807/148019
U2 - 10.1016/S2213-2600(19)30416-3
DO - 10.1016/S2213-2600(19)30416-3
M3 - Article
SN - 2213-2600
VL - 8
SP - e1-N/A
JO - The Lancet Respiratory Medicine
JF - The Lancet Respiratory Medicine
ER -